SCHEMBL3696758

SCHEMBL3696758

CC(Br)OCC[N+](C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 2/20 0.42
SCN2A Q99250 2/20 0.42
SCN3A Q9NY46 2/20 0.42
CYP2C19 P33261 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
CHRM5 P08912 6/20 0.36
CHRM1 P11229 6/20 0.36
CHRM3 P20309 6/20 0.36
CHRM2 P08172 5/20 0.36
CHRM4 P08173 5/20 0.36
CHRNB2 P17787 4/20 0.36
CHRNA4 P43681 4/20 0.36
CHRNA7 P36544 3/20 0.36
HTR1A P08908 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ADRA2A P08913 1/20 0.36
ADRA1A P35348 1/20 0.36
PGR P06401 1/20 0.36
TBXA2R P21731 1/20 0.36
CHRNB4 P30926 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5944501 0.78 SCN1A (0.45) SCN1ASCN2ASCN3ACYP2C19L3MBTL1
Hydrochloric Acid SCHEMBL22409396 0.76 SCN1A (0.43) SCN1ASCN2ASCN3ACYP2C19L3MBTL1
Hydrochloric Acid SCHEMBL28431629 0.76 SCN1A (0.43) SCN1ASCN2ASCN3ACYP2C19L3MBTL1
SCHEMBL28761585 0.74 SCN1A (0.42) SCN1ASCN2ASCN3ACYP2C19L3MBTL1
SCHEMBL1149415 0.74 SCN1A (0.42) SCN1ASCN2ASCN3ACYP2C19L3MBTL1
SCHEMBL3686620 0.74 SCN1A (0.42) SCN1ASCN2ASCN3ACYP2C19L3MBTL1
Hydrochloric Acid SCHEMBL9788455 0.72 SCN1A (0.41) SCN1ASCN2ASCN3ACYP2C19L3MBTL1
SCHEMBL11796373 0.71 DNM1 (0.32)
SCHEMBL21352710 0.70 SCN1A (0.43) SCN1ASCN2ASCN3ACYP2C19L3MBTL1
SCHEMBL24292362 0.70 SCN1A (0.39) SCN1ASCN2ASCN3ACYP2C19L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8554373-B2 Preparation and use of alkylating agents THE QUEEN'S MEDICAL CENTER (US) 2013-10-08 US disclosed
US-8551445-B2 Preparation and use of alkylating agents THE QUEEN'S MEDICAL CENTER (US) 2013-10-08 US disclosed
US-7776309-B2 Preparation and use of alkylating agents THE QUEEN'S MEDICAL CENTER (US) 2010-08-17 US disclosed
US-20080294289-A1 Preparation and Use of Alkylating Agents THE QUEEN'S MEDICAL CENTER (US) 2008-11-27 US disclosed
EP-1660433-A2 PREPARATION AND USE OF ALKYLATING AGENTS The Queen's Medical Center (US) 2006-05-31 EP disclosed
US-20050123475-A1 Preparation and use of alkylating agents THE QUEEN'S MEDICAL CENTER 2005-06-09 US disclosed
WO-2005009928-A2 PREPARATION AND USE OF ALKYLATING AGENTS THE QUEEN'S MEDICAL CENTER (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050123475-A1 Preparation and use of alkylating agents MGMT, MCL1, TOP2A SCN1A 2479/4885SCN2A 2343/4885SCN3A 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.